(Total Views: 589)
Posted On: 02/12/2023 11:49:07 AM
Post# of 145871
Not an expert on this stuff but I think it likely the FDA will look at it holistically and release “all of the above.” Safety component in particular has a cross study attribute requirement. Efficacy has already been demonstrated for HIV…that partial hold in particular, which is more important for Cytodyn’s future state…is a no-brainer with a gift-wrapped cross-study safety analysis.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)